Premium
IC‐P‐066: Association of FDG‐PET Brain Metabolism with Alzheimer’s Disease Risk Genes
Author(s) -
Stage Eddie,
Duran Tugce,
Risacher Shan L.,
Goukasian Naira,
Do Triet,
West John D.,
Nho Kwangsik,
Grotts Jonathan,
Apostolova Liana G.,
Elashoff David,
Saykin Andy J.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.096
Subject(s) - genome wide association study , linkage disequilibrium , biology , medicine , neuroscience , oncology , genetics , gene , single nucleotide polymorphism , genotype
and 2 indicate that FHVL’s showed significantly less memory decline relative to S/S’s over 7-9 years in WRAP and 3 years in ADNI, whereas FH+ VL’s showed more decline. FHVL’s showed less MTL CT atrophy over 3 years than S/S’s in ADNI (Figure 3), whereas FH+ VL’s showed more atrophy. FHVL’s had less MTL hypometabolism, such as in WRAP (Figure 4). Finally, FHand FH+ VL’s respectively showed 20% lower and higher IR in both cohorts. IR mediated FH*TOMM40 effects on brain pathology. Conclusions: Findings in both late middle-aged and elder cohorts suggest that FH strongly changes the effect of TOMM40 on cognitive, neuroimaging, and metabolic outcomes. Accounting for FH may resolve discrepancies in the TOMM40 literature.